Yorvipath’s approval showcases biopharma’s interest in rare endocrine disorder

Kyle LaHucik

Senior Reporter

Michele Rayes used to take 64 pills a day to manage her hypoparathyroidism, a rare endocrine disorder that impairs calcium levels, dampens daily quality of …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Yorvipath’s approval showcases biopharma’s interest in rare endocrine disorder

Kyle LaHucik

Senior Reporter

Sign up to read this article for free.

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

CBER's deputy director departs as staff shakeup continues

Bluebird bio to sell to investment funds after struggling to make money from gene therapies

Eli Lilly stockpiles $548M of oral weight loss drug ahead of launch

FDA approves first drug to treat ultra-rare lipid storage disease

Will CRISPR matter?

Trusted protection: Why the current meningococcal vaccination schedule shouldn’t change without strong evidence

Yorvipath’s ap­proval show­cas­es bio­phar­ma’s in­ter­est in rare en­docrine dis­or­der

Senior Reporter

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

Yorvipath’s approval showcases biopharma’s interest in rare endocrine disorder